Data-driven drug repositioning using olfactory omics profiles:challenges and perspectives in neurodegeneration  

作　　者：Paz Cartas-Cejudo Adriana Cortés Mercedes Lachén-Montes Elena Anaya-Cubero Joaquín Fernández-Irigoyen Enrique Santamaría 

机构地区：[1]Clinical Neuroproteomics Unit,Proteomics Platform,Navarrabiomed,Hospitalario Universitario de Navarra(HUN),Universidad Pública de Navarra(UPNA),IdiSNA,Navarra Institute for Health Research,Pamplona,Spain

出　　处：《Neural Regeneration Research》2025年第7期1997-1998,共2页中国神经再生研究（英文版）

基　　金：funded by grants from the Spanish Ministry of Science,Innovation and Universities(Ref.PID2019-110356RB-I00/AEI/10.13039/501100011033)to JFI and ES;the Department of Economic and Business Development from Government of Navarra(Ref.0011-1411-2023-000028 to ES);supported by a predoctoral fellowship from the Public University of Navarra(UPNA);supported by a postdoctoral fellowship from Miguel Servet Foundation-Navarrabiomed;supported by“Programa MRR Investigo 2023”in the framework of the European Union recovery and resilience facility。

摘　　要：Data-driven drug repositioning using olfactory omics profiles-challenges and perspectives in neurodegeneration:Neurodegenerative diseases are characterized by progressive degeneration and loss of neuronal function in the central nervous system.These diseases are often characterized as proteinopathies,which are disorders primarily driven by the aggregation or misfolding of specific amyloid proteins within cells,leading to their dysfunction and eventual death.Despite the gain-of-function hypothesis related to the aggregation of these proteins,recently,an alternative hypothesis regarding the loss-of-function of the soluble monomeric proteins during the process of aggregation into amyloids is gaining currency.This last event is called proteinopenia and refers to conditions characterized by a deficiency or decrease in the levels of specific soluble proteins in the body(Ezzat et al.,2023).It has been demonstrated that levels of soluble proteins involved in neurodegenerative diseases are decreased.

关 键 词：DISEASES drug AMYLOID 

分 类 号：R741[医药卫生—神经病学与精神病学]